Stem Cell and Transplantation Biology

干细胞和移植生物学

• 批准号: 10472478
• 负责人: DEREK L STIREWALT
• 金额: $ 63.28万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10472478
• 关键词: Address; Adherence; Advisory Committees; Animal Model; Area; Award; Biological Assay; Biological Products; Biology; Biomedical Research; CD34 gene; Canis familiaris; Cells; Charge; Chimerism; Collaborations; Communities; Consultations; Country; Development; Direct Costs; Disease model; Doctor of Philosophy; Dog Diseases; Educational workshop; Ensure; Faculty; Fee-for-Service Plans; Fred Hutchinson Cancer Research Center; Funding; Gene Expression; Gene-Modified; Genes; Goals; Grant; Hematological Disease; Hematology; Hematopoiesis; Human; In Vitro; Income; Individual; Institution; Internships; Liquid substance; Logistics; Measurement; Measures; Mediating; Modeling; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Nitrogen; Non-Malignant; Patients; Persons; Pilot Projects; Positioning Attribute; Pre-Clinical Model; Procedures; Process; Production; Protocols documentation; Pyruvate Kinase; Quality Control; Research; Research Personnel; Resources; Science; Services; Shipping; Ships; Site; Speed; Spumavirus; Stem cell transplant; Training; Transplantation; Travel; Underrepresented Populations; Underrepresented Students; Underserved Population; Universities; Viral; Washington; Work; Xenograft procedure; base; canine model; cost; cost effective; data sharing; design; experience; gene therapy; genetic manipulation; graft vs host disease; in vivo; in vivo Model; in vivo evaluation; member; new technology; novel therapeutics; online community; organizational structure; outcome prediction; pre-clinical; prevent; programs; quality assurance; ranpirnase; recruit; safety outcomes; stem; stem cells; tool; transplant model; transplantation therapy; treatment response; virtual; web site

PROJECT SUMMARY/ABSTRACT - Overall The theme of this CCEH is focused on stem cell and transplantation biology. The aims are designed to overcome obstacles that prevent new investigators from joining this field. Specifically the four cores will provide investigators access to: Large numbers of human and canine stem/progenitor cells; Scalable viral production services for AAV, gamma-, lenti- and foamy viruses; Products for precision gene editing and functional genetic manipulation; PCR assays for tracking chimerism, and insertion sites; Xenografting to assess human hematopoiesis; Large animal model for preclinical in vivo testing and disease modeling. The major goal of this CCEH is to make these services available throughout the US. For this purpose, products and services must be cost- effective and of high quality. Also training in best practices for the use of these resources is imperative. Towards this goal core staff provide on-site training: funds to support travel to attend training sessions are available. In addition, standard operating procedures (SOP) and quality control measures (QC) for all processes and products are shared on our website where they can be discussed and amended as the science evolves. The logistics of distributing products throughout the country are challenging. However, since the first iteration of this grant (P30 DK056465) in 1999 we have successfully shipped highly purified CD34 cells in liquid nitrogen to hundreds of satisfied investigators. Our costs are generally less than 1/3 of the cheapest commercial vender, and our product is better. Logistics for shipping other biological products to out of state users are already in place. The fees for service charged by this CCEH generates program income of $1-2 million per year. These funds are used to increase staff, develop new technologies and to fund the Enrichment Program. The goal is to help build a strong, diverse, interactive hematology research community. Included in this effort is a research internship program for students from underrepresented or underserved populations. The Seattle CCEH research base consists of 25 faculty members at the University of Washington and/or the Fred Hutchinson Cancer Research Center. Currently our research base brings in $17,130,946 in direct costs per year for studies in non-malignant hematopoiesis.

项目摘要/摘要 - 总体 该CCEH的主题集中在干细胞和移植生物学上。目的设计为 克服阻止新研究人员加入该领域的障碍。特别是四个核心 为研究人员提供：大量的人类和犬类茎/祖细胞；可扩展病毒 为AAV，γ-，扁豆和泡沫病毒的生产服务；精确基因编辑的产品 功能性遗传操作；追踪嵌合和插入部位的PCR测定； Xenografting到 评估人类造血；用于临床前体内测试和疾病模型的大型动物模型。 此CCEH的主要目标是使这些服务在美国各地可用。为此， 产品和服务必须具有成本效益和高质量。还培训了最佳实践的使用 这些资源是必须的。朝目标核心人员提供现场培训：支持旅行的资金 可以参加培训课程。此外，标准操作程序（SOP）和质量 所有流程和产品的控制措施（QC）都在我们的网站上共享 随着科学的发展而讨论并修改。 在全国范围内分销产品的物流具有挑战性。但是，自第一个 这项拨款（P30 DK056465）在1999年的迭代成功，我们成功地运送了高度纯化的CD34细胞 液氮对数百个满足的研究人员。我们的费用通常小于最便宜的1/3 商业供应商，我们的产品更好。将其他生物产品运送到州外的物流 用户已经到位。 该CCEH收取的服务费用每年产生1-200万美元的计划收入。这些资金 用于增加员工，开发新技术并资助丰富计划。目标是 帮助建立一个强大，多样，互动的血液学研究界。这项工作包括一项研究 来自代表性不足或服务不足的学生的实习计划。 西雅图CCEH研究基础由华盛顿大学的25名教职员工组成和/或 弗雷德·哈钦森癌症研究中心。目前，我们的研究基础带来了17,130,946美元的直接费用 每年进行非恶性造血的研究。